Enlarge
 

Home-brew methods based on mitogens (e.g. ConA, PHA,  PWM etc.), plate-bound/soluble antibodies, or chemical activators give a generic, non-physiological activation that is hard to predict and repeat with consistency. 

Figure 1. Dynabeads® technology is the fastest growing method for T cell activation. Graphs show percent increase/decrease of published papers using Dynabeads® (red) and alternative methods over the last 6 years. Source: Google Scholar, Jan. 2015.

Dynabeads® T-Activator CD3/CD28 products for human and mouse are ideal for short time stimulation studies and T cell expansion of polyclonal T cells (e.g T cell subsets isolated from whole blood, MNC or tissue digests).

"I used the CD3/CD28 Dynabeads® for my proliferation experiment, and the experiment worked beautifully!  I have been trying to get to work for a couple of months using soluble CD28/CD3, and it was just not happening. Dynabeads® have definitely made my day!"

Lisa S. Thomas, Research Associate IV, Cedars-Sinai Medical Center

 

Key Benefits

  • Ease-of-use: No need to prepare autologous APC, feeder cells, or antigen. No need to pre-coat antibodies to beads.
  • Physiological activation: Simultaneous signals with agonistic monoclonal antibodies to CD3/TCR and CD28.
  • Stimulate and re-stimulate: Release and remove the magnetic beads. Cells can be re-stimulated several times.
  • Reliability: Cells keep their functionality with a cytokine profile and a full T cell repertoire reflecting that of in vivo settings.
 

Main applications

The Dynabeads® technology allows you to activate and/or expand naïve and memory T cells, T cell clones, regulatory T cells, NKT cells and CTLs from mouse and human samples.

The technology allows for the activation of  T cells for signaling experiments (proteomics), T cell expansion, T helper cell differentiation (Th1, Th2, Th17), expansion of regulatory T cells and T cell activation for improved transduction efficiency of MNC/T cells.  A clinical research grade version is also available, allowing you to move from mouse studies to clinical research using the same technology platform.

The main application for these products is T cell re-stimulation and expansion of antigen-specific (Ag-specific) T cells from cell lines, cell clones or freshly isolated/enriched Ag-specific T cells.

Key benefits:

  • Physiological activation: Stimulation of CD3/TCR, CD28 and CD137 with agonistic monoclonal antibodies
  • Efficiency: Increased expansion and survival of Ag-specific T cells
  • Reliability: T cells expanded with Dynabeads maintain Ag-specificity when tested in bioassays
  • Ease- of-use: No need to find or prepare donor matched APCs or antigen

To allow for expansion of human antigen-specific T cells, the Dynabeads® are conjugated with anti-CD3, anti-CD28, and anti-CD137 antibodies. CD137 (4-1BB) is a member of the tumor necrosis factor family and agonistic anti-CD137 antibodies act as an activating co-stimulatory molecule especially important for effector/ memory T cells and promote the survival and proliferation of T lymphocytes. 

This  technology allows you to activate and/or expand naïve and memory T cells, T cell clones, regulatory T cells, NKT cells and CTLs from mouse and human samples. A clinical research grade product is also available, allowing you to move from mouse studies to clinical research using the same technology platform.

The new Dynabeads® T-Activator CD3/CD28/CD137 for expansion of human antigen-specific T cells are conjugated with anti-CD3, anti-CD28, and anti-CD137 antibodies. CD137 (4-1BB) is a member of the tumor necrosis factor family and agonistic anti-CD137 antibodies act as an activating co-stimulatory molecule especially important for effector/ memory T cells and promote the survival and proliferation of T lymphocytes.


The Dynabeads® technology allows you to activate and/or expand naïve and memory T cells, T cell clones, regulatory T cells, NKT cells and CTLs from mouse and human samples.

Our full portfolio of products also include a clinical research grade version, allowing you to move from mouse studies to clinical research using the same technology platform.